Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

Combination chemotherapy can cure certain leukemias and lymphomas, but most solid
cancers are only curable at early stages. We review quantitative principles that explain the …

Cisplatin and its platinum analogs, carboplatin and oxaliplatin, are some of the most widely
used cancer chemotherapeutics. Although cisplatin and carboplatin are used primarily in …

Traditionally, intertumour heterogeneity in breast cancer has been documented in terms of
different histological subtypes, treatment sensitivity profiles, and clinical outcomes among …

Our understanding of cancer is being transformed by exploring clonal diversity, drug
resistance, and causation within an evolutionary framework. The therapeutic resilience of …

Covering: 2011 to 2014 It is widely accepted that drug discovery often requires a systems-
level polypharmacology approach to tackle problems such as lack of efficacy and emerging …

Cancer drug resistance is a major problem, with the majority of patients with metastatic
disease ultimately developing multidrug resistance and succumbing to their disease. Our …

Cancer is often considered a genetic disease. However, much of the enormous plasticity of
cancer cells to evolve different phenotypes, to adapt to challenging microenvironments and …

The extracellular matrix (ECM) is a salient feature of all solid tissues within the body. This
complex, acellular entity is composed of hundreds of individual molecules whose assembly …

The computational prediction of drug responses based on the analysis of multiple types of
genome-wide molecular data is vital for accomplishing the promise of precision medicine in …